A clinical oral rehabilitation program significantly reduced salivary antimicrobial peptide levels, increased saliva flow, and improved oral health quality of life in dementia patients over 6 months.
Effect Size 1.31 for Quality of LifeDementia patients receiving oral rehabilitation showed large improvements in oral health quality of life at 6 months, predicted by earlier changes in salivary antimicrobial peptide levels
What the researchers found
In this RCT of 55 dementia patients, the experimental group receiving oral rehabilitation showed significantly lower histatin-5 (HTN-5) levels at 3 months (β=-0.08, effect size=0.72), improved salivary flow rate at 6 months (β=0.89, ES=0.89), and better oral health quality of life at 6 months (β=6.99, ES=1.31) compared to controls. Changes in salivary flow rate (β=4.03), HTN-5 level (β=-0.78), and beta-defensin 2 level (β=-0.91) at 3 months all predicted improved quality of life at 6 months (all p<0.05).
Why it matters
Dementia patients are at high risk for poor oral health, which is linked to aspiration pneumonia, nutritional decline, and reduced quality of life. This study shows that salivary antimicrobial peptides — histatin-5 and beta-defensin 2 — can serve as measurable biomarkers of oral health improvement, providing objective evidence that oral rehabilitation programs work and offering a new way to monitor oral health in patients who may struggle to report symptoms.
How the study worked
This was a randomized controlled trial with 55 dementia patients (28 experimental, 27 control). Both groups received oral health information leaflets. The experimental group additionally received individualized oral muscle exercises and oral self-care practice. Saliva samples and oral health quality of life data were collected at baseline and follow-up. Changes were analyzed using generalized estimating equation models.
What this study cannot tell us
The sample size of 55 patients is relatively small for an RCT. The study did not assess specific oral pathogens, so the relationship between peptide changes and microbial ecology is unclear. Dementia severity varied, which could influence both oral care compliance and outcomes. The 6-month follow-up may not capture long-term effects.
How to read the evidence
This is a randomized controlled trial — a strong study design. While the sample size is small (n=55), the use of randomization, objective biomarkers (salivary peptide levels), and validated quality of life measures provides moderate-to-strong evidence.
When this study was published
Published in 2025, this study represents current research at the intersection of antimicrobial peptide biology, oral health, and neurodegenerative disease.
The bigger picture
Antimicrobial peptides are increasingly recognized as biomarkers for disease states beyond infection. This study connects salivary AMPs to neurodegenerative disease through oral health, contributing to the growing understanding that oral microbiome changes — reflected in AMP levels — may be linked to dementia pathogenesis and disease progression.
Questions still open
- Could elevated salivary antimicrobial peptide levels serve as early biomarkers for dementia-related oral health decline?
- Do the reductions in histatin-5 and beta-defensin 2 reflect actual changes in oral microbial load and inflammation?
- Would longer-term oral rehabilitation programs produce sustained peptide and quality of life improvements in dementia patients?
Common questions
What are salivary antimicrobial peptides and why do they matter for dementia?
Can oral exercises really improve quality of life for dementia patients?
Read the original research
Salivary Antimicrobial Peptide in Patients With Dementia Before and After Clinical Oral Rehabilitation Programme: A Randomised Controlled Trial.
Journal of oral rehabilitation, 52(1), 1-8
Citation
Chen, Ming-An; Yang, Yuan-Han; Liu, Ching-Kuan; Matsuo, Koichiro; Hsu, Chih-Cheng; Lin, Ying-Chu; Huang, Hsiao-Ling. (2025). Salivary Antimicrobial Peptide in Patients With Dementia Before and After Clinical Oral Rehabilitation Programme: A Randomised Controlled Trial.. Journal of oral rehabilitation, 52(1), 1-8. https://doi.org/10.1111/joor.13867